2 weeks Ago By ABMN Staff
Merck & Co., Inc. ( NYSE:MRK – Get Free Report ) shares shot up 0.
6% during mid-day trading on Friday . The company traded as high as $114.34 and last traded at $113.
81. 2,561,677 shares were traded during mid-day trading, a decline of 71% from the average session volume of 8,712,832 shares. The stock had previously closed at $113.
09. Analysts Set New Price Targets MRK has been the topic of several analyst reports. Wells Fargo & Company reduced their price target on Merck & Co.
, Inc. from $140.00 to $125.
00 and set an “equal weight” rating on the stock in a report on Wednesday, July 31st. Argus upgraded shares of Merck & Co., Inc.
to a “strong-buy” rating in a report on Wednesday, June 5th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Merck & Co.
, Inc. in a report on Monday, September 16th. Wolfe Research upgraded Merck & Co.
, Inc. to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, Bank of America lowered their price objective on Merck & Co.
, Inc. from $150.00 to $145.
00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.
com, the company has an average rating of “Buy” and an average price target of $134.58. Check Out Our Latest Stock Analysis on Merck & Co.
, Inc. Merck & Co., Inc.
Trading Up 0.5 % Merck & Co., Inc.
( NYSE:MRK – Get Free Report ) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.
16 by $0.12. The business had revenue of $16.
10 billion for the quarter, compared to analysts’ expectations of $15.87 billion. Merck & Co.
, Inc. had a net margin of 21.99% and a return on equity of 40.
69%. The business’s quarterly revenue was up 7.1% on a year-over-year basis.
During the same quarter in the prior year, the company earned ($2.06) earnings per share. On average, research analysts anticipate that Merck & Co.
, Inc. will post 8.01 earnings per share for the current year.
Merck & Co., Inc. Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Monday, October 7th.
Shareholders of record on Monday, September 16th will be paid a $0.77 dividend. The ex-dividend date is Monday, September 16th.
This represents a $3.08 annualized dividend and a dividend yield of 2.71%.
Merck & Co., Inc.’s dividend payout ratio (DPR) is 342.
22%. Institutional Inflows and Outflows A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Industrial Alliance Investment Management Inc.
boosted its stake in shares of Merck & Co., Inc. by 2.
6% in the 1st quarter. Industrial Alliance Investment Management Inc. now owns 3,193 shares of the company’s stock valued at $421,000 after buying an additional 80 shares during the period.
IRON Financial LLC lifted its stake in Merck & Co., Inc. by 4.
6% in the second quarter. IRON Financial LLC now owns 1,811 shares of the company’s stock worth $224,000 after acquiring an additional 80 shares during the last quarter. Argent Capital Management LLC grew its holdings in Merck & Co.
, Inc. by 0.8% during the 2nd quarter.
Argent Capital Management LLC now owns 10,521 shares of the company’s stock worth $1,302,000 after acquiring an additional 81 shares in the last quarter. Forza Wealth Management LLC increased its position in shares of Merck & Co., Inc.
by 0.8% in the 2nd quarter. Forza Wealth Management LLC now owns 10,480 shares of the company’s stock valued at $1,297,000 after purchasing an additional 82 shares during the last quarter.
Finally, Vista Investment Partners LLC raised its holdings in shares of Merck & Co., Inc. by 2.
0% in the 2nd quarter. Vista Investment Partners LLC now owns 4,164 shares of the company’s stock valued at $516,000 after purchasing an additional 82 shares in the last quarter. 76.
07% of the stock is currently owned by hedge funds and other institutional investors. Merck & Co., Inc.
Company Profile ( Get Free Report ) Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Further Reading Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co.
Inc. and related companies with MarketBeat.com's FREE daily email newsletter .
.
